Plus Therapeutics, Inc.
PSTV
$0.7691
-$0.075-8.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -3.02% | 13.84% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -3.02% | 13.84% | |||
| Cost of Revenue | -23.51% | 3.07% | |||
| Gross Profit | 44.79% | 6.16% | |||
| SG&A Expenses | 30.41% | 8.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.08% | 5.61% | |||
| Operating Income | -2.66% | -2.76% | |||
| Income Before Tax | -35.80% | 2.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -35.80% | 2.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -35.80% | 2.24% | |||
| EBIT | -2.66% | -2.76% | |||
| EBITDA | -2.81% | -2.07% | |||
| EPS Basic | -35.68% | 19.11% | |||
| Normalized Basic EPS | -35.64% | 19.10% | |||
| EPS Diluted | -34.14% | 47.93% | |||
| Normalized Diluted EPS | -35.64% | -33.74% | |||
| Average Basic Shares Outstanding | 0.11% | 20.84% | |||
| Average Diluted Shares Outstanding | 0.11% | -26.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||